Imidazo[1,2-α]pyridines.: Part 2:: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors

被引：113

作者：

Byth, KF ^{[1
]}

Culshaw, JD ^{[1
]}

Green, S ^{[1
]}

Oakes, SE ^{[1
]}

Thomas, AP ^{[1
]}

机构：

[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 09期

关键词：

CDK2; inhibitor;

D O I：

10.1016/j.bmcl.2004.02.015

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions Of Substitution, which allow modification of physical properties and offer the potential for in vivo optimisation. (C) 2004 Elsevier Ltd. All rights reserved.

引用

收藏

页码：2245 / 2248

页数：4

相关论文

共 26 条

[11] Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1 [J].

Harbour, JW ;

Luo, RX ;

Santi, AD ;

Postigo, AA ;

Dean, DC .

CELL, 1999, 98 (06) :859-869

[12] Structure-based generation of a new class of potent Cdk4 inhibitors:: New de novo design strategy and library design [J].

Honma, T ;

Hayashi, K ;

Aoyama, T ;

Hashimoto, N ;

Machida, T ;

Fukasawa, K ;

Iwama, T ;

Ikeura, C ;

Ikuta, M ;

Suzuki-Takahashi, I ;

Iwasawa, Y ;

Hayama, T ;

Nishimura, S ;

Morishima, H .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (26) :4615-4627

[13] A novel approach for the development of selective Cdk4 inhibitors: Library design based on locations of Cdk4 specific amino acid residues [J].

Honma, T ;

Yoshizumi, T ;

Hashimoto, N ;

Hayashi, K ;

Kawanishi, N ;

Fukasawa, K ;

Takaki, T ;

Ikeura, C ;

Ikuta, M ;

Suzuki-Takahashi, I ;

Hayama, T ;

Nishimura, S ;

Morishima, H .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (26) :4628-4640

[14] S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells [J].

Hu, B ;

Mitra, J ;

van den Heuvel, S ;

Enders, GH .

MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (08) :2755-2766

[15] Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities [J].

Kim, KS ;

Kimball, SD ;

Misra, RN ;

Rawlins, DB ;

Hunt, JT ;

Xiao, HY ;

Lu, SF ;

Qian, LG ;

Han, WC ;

Shan, WF ;

Mitt, T ;

Cai, ZW ;

Poss, MA ;

Zhu, H ;

Sack, JS ;

Tokarski, JS ;

Chang, CY ;

Pavletich, N ;

Kamath, A ;

Humphreys, WG ;

Marathe, P ;

Bursuker, I ;

Kellar, KA ;

Roongta, U ;

Batorsky, R ;

Mulheron, JG ;

Bol, D ;

Fairchild, CR ;

Lee, FY ;

Webster, KR .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3905-3927

[16] Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors [J].

Li, XY ;

Huang, P ;

Cui, JJ ;

Zhang, J ;

Tang, C .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (11) :1939-1942

[17] 4-alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2 [J].

Mesguiche, V ;

Parsons, RJ ;

Arris, CE ;

Bentley, J ;

Boyle, FT ;

Curtin, NJ ;

Davies, TG ;

Endicott, JA ;

Gibson, AE ;

Golding, BT ;

Griffin, RJ ;

Jewsbury, P ;

Johnson, LN ;

Newell, DR ;

Noble, MEM ;

Wang, LZ ;

Hardcastle, IR .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (02) :217-222

[18] A highly active palladium catalyst system for the arylation of anilines [J].

Sadighi, JP ;

Harris, MC ;

Buchwald, SL .

TETRAHEDRON LETTERS, 1998, 39 (30) :5327-5330

[19] Palladium-catalyzed cyanation of aryl and heteroaryl iodides with copper(I) cyanide [J].

Sakamoto, T ;

Ohsawa, K .

JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1999, (16) :2323-2326

[20] Preclinical and clinical development of cyclin-dependent kinase modulators [J].

Senderowicz, AM ;

Sausville, EA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (05) :376-387